Cargando…

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.

Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Raderer, M., Kurtaran, A., Hejna, M., Vorbeck, F., Angelberger, P., Scheithauer, W., Virgolini, I.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062941/
https://www.ncbi.nlm.nih.gov/pubmed/9662242
_version_ 1782137234299813888
author Raderer, M.
Kurtaran, A.
Hejna, M.
Vorbeck, F.
Angelberger, P.
Scheithauer, W.
Virgolini, I.
author_facet Raderer, M.
Kurtaran, A.
Hejna, M.
Vorbeck, F.
Angelberger, P.
Scheithauer, W.
Virgolini, I.
author_sort Raderer, M.
collection PubMed
description Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods. IMAGES:
format Text
id pubmed-2062941
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20629412009-09-10 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Raderer, M. Kurtaran, A. Hejna, M. Vorbeck, F. Angelberger, P. Scheithauer, W. Virgolini, I. Br J Cancer Research Article Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods. IMAGES: Nature Publishing Group|1 1998-07 /pmc/articles/PMC2062941/ /pubmed/9662242 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Raderer, M.
Kurtaran, A.
Hejna, M.
Vorbeck, F.
Angelberger, P.
Scheithauer, W.
Virgolini, I.
123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
title 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
title_full 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
title_fullStr 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
title_full_unstemmed 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
title_short 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
title_sort 123i-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062941/
https://www.ncbi.nlm.nih.gov/pubmed/9662242
work_keys_str_mv AT radererm 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer
AT kurtarana 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer
AT hejnam 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer
AT vorbeckf 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer
AT angelbergerp 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer
AT scheithauerw 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer
AT virgolinii 123ilabelledvasoactiveintestinalpeptidereceptorscintigraphyinpatientswithcolorectalcancer